ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Carcinoma, Non-Small-Cell Lung is on this study

  • ClinicalTrials.gov files the study under Carcinoma, Non-Small-Cell Lung.
  • GPT-6.1 Sol (High) judged the term right: what the study is about. Oct 20 (day only)
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Carcinoma, Non-Small-Cell Lung.
  • Rule based: the finest condition the study states.
8 links0 made here, not in the record16 judgments3 judges (the rules as one: Rule based)2 record changes seen
GPT-6.1 Sol (High)Model not recordedRule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT04736173Study EvaluatingEffectiveness and Safety ofZimberelimab andDomvanalimab in Lung CancerArcus Biosciences, Inc.Phase 2 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 5 · ClinicalTrials.gov record · Version of 2026-10-05Oct 19 · ClinicalTrials.gov record · Version of 2026-10-19Version of 2026-10-19CONDITIONSCarcinoma, Non-Small-Cell L…The registry's MeSH filing›Oct 20 · GPT-6.1 Sol (High) · RightNov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionLung NeoplasmsThe registry's MeSH filing›Nov 14 · Rule based · Wider: a narrower term is filedWider: a narrower term is filedDRUGSDomvanalimabIntervention entry›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedZimberelimabIntervention entry›Nov 1 · A model not recorded · TestedNov 18 · Rule based · TestedTestedCarboplatinIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · ComparatorComparatorPemetrexedIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · ComparatorComparatorPembrolizumabIntervention entry›Nov 1 · A model not recorded · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
2 versions of the record seen on ClinicalTrials.gov, Oct 5–Oct 19 · changes seen, not judgments
Oct 20Carcinoma, Non-Small-Cell LungGPT-6.1 Sol (High)RightCurrent
Nov 1DomvanalimabA model not recordedTestedCurrent
Nov 1ZimberelimabA model not recordedTestedCurrent
Nov 1CarboplatinA model not recordedComparatorCurrent
Nov 1PaclitaxelA model not recordedComparatorCurrent
Nov 1PemetrexedA model not recordedComparatorCurrent
Nov 1PembrolizumabA model not recordedComparatorCurrent
Nov 14Carcinoma, Non-Small-Cell LungRule based · condition-kind ruleFinest filed termCurrent
Nov 14Lung NeoplasmsRule based · condition-kind ruleWider: a narrower term is filedCurrent
Nov 18DomvanalimabRule based · role ruleTestedAgrees
Nov 18ZimberelimabRule based · role ruleTestedAgrees
Nov 18CarboplatinRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleComparatorAgrees
Nov 18PemetrexedRule based · role ruleComparatorAgrees
Nov 18PembrolizumabRule based · role ruleComparatorAgrees
As of nowCarcinoma, Non-Small-Cell LungRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.